CHIMERA Challenge: Biochemical Recurrence Prediction in Prostate Cancer Patients using multimodal datasets

• URL: http://arxiv.org/abs/2608.21497v1
• Date: Fri, 21 Aug 2026 15:23:06 GMT
• Title: CHIMERA Challenge: Biochemical Recurrence Prediction in Prostate Cancer Patients using multimodal datasets
• Abstract summary: CHIMERA is the first public, standardized multimodal benchmark for prostate cancer prognosis.<n>The dataset comprises 801 MRI sequences, 13 clinical variables per case, and 942 WSIs.
• Score: 1.4186847785236487
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Biochemical recurrence (BCR), defined as any detectable prostate-specific antigen level after prostatectomy with confirmatory elevation, is widely used as a surrogate endpoint and typically assessed using clinical and pathological variables. Currently, no standardized benchmark exists for multimodal prognostic modeling in urological cancers, partly because curating heterogeneous multimodal data remains challenging. We developed the CHIMERA Challenge, a multimodal benchmark integrating preoperative mpMRI, post-prostatectomy histopathology, patient characteristics, and clinician-derived variables from 267 patients across two institutions. The dataset comprises 801 MRI sequences, 13 clinical variables per case, and 942 WSIs. Training (n=95), validation (n=23), and test (n=149) splits were established and hosted on the Grand Challenge platform. Baseline clinical and pathological characteristics did not differ significantly across splits. Models were evaluated on predicting time to BCR using the C-index. Post-challenge analyses tested how each model type performed when clinician-derived variables were withheld or randomized. Unimodal clinical models achieved the highest test C-index of 0.7402 but proved sensitive to the integrity of these variables, with performance collapsing toward chance (C approximately 0.50) when they were randomized. Multimodal models retained near-baseline performance when these variables were withheld (delta C at most 0.04), indicating their ability to recover prognostic signal directly from imaging data. CHIMERA is the first public, standardized multimodal benchmark for prostate cancer prognosis. Although models using only patient characteristics and clinician-derived variables yielded the highest leaderboard performance, multimodal models demonstrated greater robustness in clinically realistic scenarios where complete expert annotation is not guaranteed.

Related papers

• Histopathological Spectrum-Guided Prostate Stratification via Segmentation-Assisted Diagnostic Transformer [29.021037203684227]
  We construct a Prostate Cancer Histopathology Spectrum dataset (PCa-HSD)<n>We formulate a clinically meaningful four-class classification task, addressing the underrepresentation of benign lesions that are easily confounded with prostate cancer in existing datasets.<n>Our proposed method consistently improves accuracy across backbones, achieving the best average accuracy of 0.633 and JointRecall of 0.768 in five-fold cross-validation on a cohort of 344 patients.
  arXiv  Detail & Related papers  (2026-07-19T10:03:47Z)
• Evaluating Large Language Models in Dynamic Clinical Decision-Making with Standardized Patient Cases [71.12461204050985]
  MedSP1000 is an SP-derived interactive benchmark for clinical-agent evaluation.<n>It converts peer-reviewed SP teaching cases into executable scenarios with defined SP case scripts, clinical environment contexts, and human-validated structured rubrics.<n>Applying MedSP1000 to a range of general-purpose and medically specialized LLMs, we find that performance on static benchmarks does not reliably translate to such educational scenarios.
  arXiv  Detail & Related papers  (2026-06-03T17:17:16Z)
• Simulating clinical interventions with a generative multimodal model of human physiology [49.828582089394445]
  HealthFormer is a decoder-only transformer that models the human physiological trajectory generatively.<n>We tokenise each participant's health trajectory across 667 measurements spanning seven domains.<n>HealthFormer improves prediction for 27 of 30 incident-disease and mortality endpoints, exceeding established clinical risk scores in every comparison.
  arXiv  Detail & Related papers  (2026-04-30T14:10:30Z)
• Cerebra: A Multidisciplinary AI Board for Multimodal Dementia Characterization and Risk Assessment [56.62016795093786]
  Cerebra is an interactive multi-agent AI team that coordinates specialized agents for EHR, clinical notes, and medical imaging analysis.<n>It supports privacy-preserving deployment by operating on structured representations and remains robust when modalities are incomplete.<n>Cerebra significantly improved expert performance, increasing accuracy by 17.5 percentage points in prospective dementia risk estimation.
  arXiv  Detail & Related papers  (2026-03-23T05:46:45Z)
• LiveClin: A Live Clinical Benchmark without Leakage [50.45415584327275]
  LiveClin is a live benchmark designed for approximating real-world clinical practice.<n>We transform authentic patient cases into complex, multimodal evaluation scenarios that span the entire clinical pathway.<n>Our evaluation of 26 models on LiveClin reveals the profound difficulty of these real-world scenarios, with the top-performing model achieving a Case Accuracy of just 35.7%.
  arXiv  Detail & Related papers  (2026-02-18T03:59:46Z)
• One-shot synthesis of rare gastrointestinal lesions improves diagnostic accuracy and clinical training [45.49415063761575]
  EndoRare is a one-shot, retraining-free generative framework that synthesizes diverse, high-fidelity lesion exemplars from a single reference image.<n>We validated the framework across four rare pathologies.<n>These results establish a practical, data-efficient pathway to bridge the rare-disease gap in both computer-aided diagnostics and clinical education.
  arXiv  Detail & Related papers  (2025-12-30T15:07:09Z)
• PathBench: A comprehensive comparison benchmark for pathology foundation models towards precision oncology [33.51485504161335]
  We present PathBench, the first comprehensive benchmark for pathology foundation models (PFMs)<n>Our framework incorporates large-scale data, enabling objective comparison of PFMs.<n>We have collected 15,888 WSIs from 8,549 patients across 10 hospitals, encompassing over 64 diagnosis and prognosis tasks.
  arXiv  Detail & Related papers  (2025-05-26T16:42:22Z)
• A multimodal ensemble approach for clear cell renal cell carcinoma treatment outcome prediction [6.199310532720352]
  We developed a multi-modal ensemble model (MMEM) that integrates clinical data, multi-omics data, and histopathology whole slide image (WSI) data.<n>MMEM predicted overall survival (OS) and disease-free survival (DFS) for ccRCC patients.
  arXiv  Detail & Related papers  (2024-12-10T02:51:14Z)
• Multi-modal AI for comprehensive breast cancer prognostication [18.691704371847855]
  We developed a novel artificial intelligence (AI)-based approach that integrates digital pathology with clinical data.<n>The test was developed and evaluated using data from a total of 8,161 female breast cancer patients across 15 cohorts.<n>Our results suggest that our AI test improves upon the accuracy of existing prognostic tests, while being applicable to a wider range of patients.
  arXiv  Detail & Related papers  (2024-10-28T17:54:29Z)
• MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response [58.0291320452122]
  This paper aims at a unified deep learning approach to predict patient prognosis and therapy response. We formalize the prognosis modeling as a multi-modal asynchronous time series classification task. Our predictive model could further stratify low-risk and high-risk patients in terms of long-term survival.
  arXiv  Detail & Related papers  (2020-10-08T15:30:17Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.